Aquinox Pharmaceuticals

Aquinox Pharmaceuticals (NASDAQ: AQXP) was a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics targeting the PI3K-delta pathway to treat inflammation, inflammatory pain, and immuno-oncology indications. The company's lead program focused on interstitial cystitis/bladder pain syndrome and oncology. Headquartered in Vancouver, British Columbia, Canada, Aquinox conducted clinical trials exploring the role of SHIP1 activators in modulating immune cell activity for cancer and inflammatory conditions. The company was listed on NASDAQ and conducted operations primarily in Canada with clinical research partnerships across North America.